Bristol-Myers Squibb Company vs PTC Therapeutics, Inc.: SG&A Expense Trends

Comparing SG&A expenses of two pharma giants over a decade.

__timestampBristol-Myers Squibb CompanyPTC Therapeutics, Inc.
Wednesday, January 1, 2014569900000044820000
Thursday, January 1, 2015500100000082080000
Friday, January 1, 2016500200000097130000
Sunday, January 1, 20174849000000121271000
Monday, January 1, 20184551000000153548000
Tuesday, January 1, 20194871000000202541000
Wednesday, January 1, 20207661000000245164000
Friday, January 1, 20217690000000285773000
Saturday, January 1, 20227814000000325998000
Sunday, January 1, 20237772000000332540000
Monday, January 1, 20248414000000
ngram

SG&A Expense Trends: Bristol-Myers Squibb vs. PTC Therapeutics

In the ever-evolving pharmaceutical industry, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Bristol-Myers Squibb Company and PTC Therapeutics, Inc. from 2014 to 2023. Over this period, Bristol-Myers Squibb consistently outspent PTC Therapeutics, with its SG&A expenses peaking in 2022 at approximately 7.8 billion dollars, a 72% increase from 2014. In contrast, PTC Therapeutics saw a more modest rise, with expenses growing by over 640% to reach around 332 million dollars in 2023. This stark difference highlights the scale and operational strategies of these companies. While Bristol-Myers Squibb's substantial investments reflect its expansive market reach, PTC Therapeutics' growth trajectory underscores its strategic focus on innovation and niche markets.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025